Xenotransplantation - Where do we go from here?
Xenotransplantation - Where do we go from here?
Learn about endpoints in Xenotransplantation and the the difference in immunosuppression regimen between Allo and Xenotransplant.
- 2:00 PM - 3:00 PM EDT
- On-demand, as part of AST's T3 webinar series.
Objectives:
After participating in this webinar, the attendee will be able to:
- Provide an overview of critical known and unknown safety endpoints in kidney Xenotransplantation
- Describe an ethical framework for identifying first living human recipients
- Learn the difference in immunosuppression regimen between Allo and Xenotransplant
- Learn how the immunosuppression for Xenotransplant was determined
Speakers:
- Jayme Locke, MD, MPH, FACS, FAST • Professor of Surgery, Chief, Division of Transplantation, Arnold G. Diethelm Endowed Chair in Transplantation Surgery, University of Alabama at Birmingham, Birmingham, AL
- Muhammad Mohiuddin, MD, D.Sc (Hon) • Professor of Surgery, Director, Xenotransplantation Program, Cardiac Xenotransplantation Program, University of Maryland School of Medicine, Baltimore, MD
Moderator:
- Stuart Knechtle, MD • William R. Kenan, Jr. Professor of Surgery, Duke Transplant Center, Department of Surgery, Duke University School of Medicine, Durham, NC
The AST Education Committee would like to thank the Community of Transplant Scientists (COTS) and the Infectious Disease Community of Practice (IDCOP) for suggesting this topic as part of the 2022-2023 T3 webinar series. Learn more about AST's COPs at www.www.myast.org/cops.
Advertisements
This content was developed independently by AST and supported by a financial contribution from
